吸附聚合物合物以适应性抑制医学膜的血液凝固激活
Tina Helmecke1, Dominik Hahn1, André Ruland1
1Leibniz Institute of Polymer Research Dresden, Institute of Biofunctional Polymer Materials, Hohe Strasse 6, Dresden 01069, Germany.
概括
这项研究开发了用于医疗器械的适应性药物释放涂层. 这些涂层有效地防止血液凝结和炎症,为血液透析膜提供了更好的安全性和性能.
科学领域:
- 生物材料科学 生物材料科学
- 聚合物化学 聚合物化学
- 血液透析技术 血液透析技术
背景情况:
- 在接口处的血液物质相互作用可以触发凝血和炎症.
- 现有的抗凝剂策略往往具有局限性和副作用.
- 血液透析膜需要有效的抗凝剂来防止治疗期间的凝血.
研究的目的:
- 开发一种适应性药物释放系统,用于对抗物质界面上的血液激活.
- 为了创建具有受控的凝反应释放动力学的氨酸排泄涂层.
- 为了使血液透析膜具有强大的抗凝固特性.
主要方法:
- 通过对凝固有反应的酸将氨酸与多聚合物 (氨酸-氨酸-无水化物) 共聚物结合.
- 将这些共聚合物作为单层吸附到聚乙硫 (PES) 表面上.
- 使用人体血和全血化评估抗凝剂作用.
- 测试功能化的聚乙硫/聚乙烯 (PES/PVP) 血液透析膜.
主要成果:
- 肝素结合的共聚物在PES表面形成稳定的单层.
- 实现了对凝血反应的肝素释放.
- 更快的肝素释放与更强的抗凝效应相关.
- PES/PVP膜显示出有效的抗凝血剂界面功能化.
结论:
- 适应性药物释放系统提供了一种有效和强大的抗凝方法.
- 这项技术为功能化血液透析膜提供了一个有前途的方法.
- 该系统的模块化允许在未来抑制多个激活过程.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
696
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
696
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


